Pharmacyte Biotech Inc.
PMCB
We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box . The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$16M
▼ -163.4% YoY
Op. Margin
–
ROIC
-16.52%
▼ -4.0pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$4M
▼ -73.0% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$18M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PMCB
Pharmacyte Biotech (PMCB) in three numbers
- Quality score
- 20/100
- Best check: share count change, -44.9%. Weakest: return on capital, -16.5%.
- Quality
Questions about Pharmacyte Biotech
Is Pharmacyte Biotech a high-quality business?
Pharmacyte Biotech scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is share count change at -44.9%, and its weakest is return on capital at -16.5%. The Quality tab shows every check against its target.
Does Pharmacyte Biotech (PMCB) pay a dividend?
No. Pharmacyte Biotech (PMCB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.9% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Sept 2026 (period ending 31 Jul 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PMCB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PMCB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.